​

Niagen Bioscience (NAGE) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

NAGE Stock Rating

Niagen Bioscience stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

NAGE Price Target Upside V Benchmarks

TypeNameUpside
StockNiagen Bioscience-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$7.60$7.60$7.60
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2514---5
Sep, 2514---5
Aug, 2522---4
Jul, 2522---4
Jun, 2523---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 06, 2025Roth CapitalBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-0.07$0.10---
Avg Forecast$-0.08$0.04$0.13$0.21$0.24
High Forecast$-0.08$0.04$0.17$0.26$0.25
Low Forecast$-0.08$0.04$0.08$0.15$0.22
Surprise %-12.50%150.00%---

Revenue Forecast

$80M $98M $116M $134M $152M $170M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$83.57M$99.60M---
Avg Forecast$83.20M$97.19M$118.50M$143.82M$164.81M
High Forecast$85.15M$98.39M$120.10M$148.40M$168.69M
Low Forecast$81.09M$95.99M$117.40M$138.30M$160.65M
Surprise %0.45%2.47%---

Net Income Forecast

$-10M $-3M $4M $11M $18M $25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-4.94M$8.55M---
Avg Forecast$-6.38M$3.19M$10.12M$17.53M$18.74M
High Forecast$-6.17M$3.29M$13.33M$20.78M$20.03M
Low Forecast$-6.57M$3.08M$6.22M$11.63M$17.44M
Surprise %-22.58%168.41%---

NAGE Forecast FAQ

Is Niagen Bioscience stock a buy?

Niagen Bioscience stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Niagen Bioscience is a favorable investment for most analysts.

What is Niagen Bioscience's price target?

Niagen Bioscience's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $7.6.

How does Niagen Bioscience stock forecast compare to its benchmarks?

Niagen Bioscience's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Niagen Bioscience over the past three months?

  • October 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Niagen Bioscience’s EPS forecast?

Niagen Bioscience's average annual EPS forecast for its fiscal year ending in December 2025 is $0.13, marking a 30.00% increase from the reported $0.1 in 2024. Estimates for the following years are $0.21 in 2026, and $0.24 in 2027.

What is Niagen Bioscience’s revenue forecast?

Niagen Bioscience's average annual revenue forecast for its fiscal year ending in December 2025 is $118.5M, reflecting a 18.98% increase from the reported $99.6M in 2024. The forecast for 2026 is $143.82M, and $164.82M for 2027.

What is Niagen Bioscience’s net income forecast?

Niagen Bioscience's net income forecast for the fiscal year ending in December 2025 stands at $10.12M, representing an 18.37% increase from the reported $8.55M in 2024. Projections indicate $17.53M in 2026, and $18.74M in 2027.